{"title":"Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I5.1938","DOIUrl":null,"url":null,"abstract":"Merck & Co. has formed a collaboration with Abide Therapeutics, a spin-out from The Scripps Research Institute, to discover, develop and commercialise small molecule therapies for the treatment of type 2 diabetes by targeting enzymes of the serine hydrolase class. Serine hydrolases represent one of the largest known enzyme families but are mostly under-explored as drug targets. The deal comes only days after Merck partnered with Pfizer to co-develop and co-commercialise ertugliflozin (PF-04971729), a sodium glucose co-transporter 2 (SGLT-2) inhibitor that is expected to enter Phase III development for type 2 diabetes later in 2013.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"58 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I5.1938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Merck & Co. has formed a collaboration with Abide Therapeutics, a spin-out from The Scripps Research Institute, to discover, develop and commercialise small molecule therapies for the treatment of type 2 diabetes by targeting enzymes of the serine hydrolase class. Serine hydrolases represent one of the largest known enzyme families but are mostly under-explored as drug targets. The deal comes only days after Merck partnered with Pfizer to co-develop and co-commercialise ertugliflozin (PF-04971729), a sodium glucose co-transporter 2 (SGLT-2) inhibitor that is expected to enter Phase III development for type 2 diabetes later in 2013.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
